The momentum of its news announced yesterday continues into today also. The stock, which had hit a new 52-week high yesterday at Rs.625, hit another new high today at Rs.655. Profit booking has pushed the stock now to Rs.630 levels.
Bajaj Healthcare, yesterday morning stated it has received approval from India's drug regulator, to manufacture and market “Ivejaj" the oral Ivermectin approved medication in India for the treatment of Covid-19 from 6th May 2021. The approval is for both domestic as well as exports.
The company has developed the active pharmacuetical ingredient (API) and the formulation for Ivermectin through its own in-house R&D team.
Most patients ailing from mild to moderate symptoms can benefit from the use of Ivejaj. The drug will be available as a prescription-based medication, with recommended doses.
Prior to this, on Tuesday, the company said that it was launching antiviral drug favipiravir for the treatment of 'mild to moderate covid-19 patients' after receiving manufacturing and marketing approval from India's drug regulator. The drug will be launched under Favijaj brand.